image: The new vibrating device improves the diagnosis of dizziness. view more
Credit: Johan Bodell/Chalmers University of Technology
Half of over-65s suffer from dizziness and problems with balance. But some tests to identify the causes of such problems are painful and can risk hearing damage. Now, researchers from Chalmers University of Technology, Sweden, have developed a new testing device using bone conduction technology, that offers significant advantages over the current tests.
Hearing and balance have something in common. For patients with dizziness, this relationship is used to diagnose issues with balance. Commonly, a 'VEMP' test (Vestibular Evoked Myogenic Potentials) needs to be performed. A VEMP test uses loud sounds to evoke a muscle reflex contraction in the neck and eye muscles, triggered by the vestibular system - the system responsible for our balance. The Chalmers researchers have now used bone conducted sounds to achieve better results.
"We have developed a new type of vibrating device that is placed behind the ear of the patient during the test," says Bo Håkansson, a professor in the research group 'Biomedical signals and systems' at Chalmers. The vibrating device is small and compact in size, and optimised to provide an adequate sound level for triggering the reflex at frequencies as low as 250 Hz. Previously, no vibrating device has been available that was directly adapted for this type of test of the balance system.
In bone conduction transmission, sound waves are transformed into vibrations through the skull, stimulating the cochlea within the ear, in the same way as when sound waves normally go through the ear canal, the eardrum and the middle ear. Bo Håkansson has over 40 years of experience in this field and has previously developed hearing aids using this technology.
Half of over-65s suffer from dizziness, but the causes can be difficult to diagnose for several reasons. In 50% of those cases, dizziness is due to problems in the vestibular system. But today's VEMP methods have major shortcomings, and can cause hearing loss and discomfort for patients.
For example, the VEMP test uses very high sound levels, and may in fact cause permanent hearing damage itself. And, if the patient already suffers from certain types of hearing loss, it may be impossible to draw any conclusions from the test. The Chalmers researchers' new method offers significant advantages.
"Thanks to this bone conduction technology, the sound levels which patients are exposed to can be minimised. The previous test was like a machine gun going off next to the ear - with this method it will be much more comfortable. The new vibrating device provides a maximum sound level of 75 decibels. The test can be performed at 40 decibels lower than today's method using air conducted sounds through headphones. This eliminates any risk that the test itself could cause hearing damage," says postdoctoral researcher Karl-Johan Fredén Jansson, who made all the measurements in the project.
The benefits also include safer testing for children, and that patients with impaired hearing function due to chronic ear infections or congenital malformations in the ear canal and middle ear can be diagnosed for the origin of their dizziness.
The vibrating device is compatible with standardised equipment for balance diagnostics in healthcare, making it easy to start using. The cost of the new technology is also estimated to be lower than the corresponding equipment used today.
A pilot study has been conducted and recently published. The next step is to conduct a larger patient study, under a recently received ethical approval, in collaboration with Sahlgrenska University Hospital in Gothenburg, where 30 participants with normal hearing will also be included.
###
More about the research
The scientific article "VEMP using a new low-frequency bone conduction transducer" has recently been published by Dove Medical Press, in the journal Medical Devices: Evidence and Research. Chalmers' partners in the study are the Sahlgrenska Academy at the University of Gothenburg, and the Danish audio companies Ortofon and Interacoustics. Grants for this project are received from Vinnova (Swedish Innovations Agency) and Hörselskadades Riksförbund (Hearing Impairment Federation).
See the researchers' own presentation of the project
Read more about research on medical signals and systems
Diagnostics for Dizziness
A common method of diagnosing the cause of dizziness is a VEMP test - Vestibular Evoked Myogenic Potentials. The test uses sound stimulation to evoke a muscle contraction in the neck and eye muscles, triggered by a reflex from the vestibular system - the system that is responsible for our sense of balance. The muscular response is measured and provides you information on whether the disorders responsible for the patient's dizziness are in the vestibular system, or in its pathways to the brain.In a traditional vestibular investigation, two variants of VEMP tests are used today: air transmitted sound through headphones or bone conducted sounds via a vibrating device attached to the head. When air transmitted sounds are used, high sound levels are required, which is uncomfortable to the patient and there is a risk of hearing damage. For bone conducted sound, the sound levels are lower, but the equipment currently available on the market is large and cumbersome, and therefore difficult to use. The new method uses new transducer technology, is smaller in size and generates bone conducted sound at a lower frequency than has been possible before (around 250 Hz). At this level, the muscle reflexes are more efficiently evoked. The muscle contractions in both the neck and the eye muscles are measured using fairly standardised equipment, so it should be easy to start incorporating it into healthcare systems.
For more information contact:
Bo Håkansson, Professor in Biomedical Engineering at the Department of Electrical Engineering at Chalmers031-772 18 07, boh@chalmers.se
Karl-Johan Fredén Jansson, Postdoctoral researcher at the Department of Electrical Engineering at Chalmers and in charge of clinical studies 031-772 17 83, karljohf@chalmers.se